drugset / Trial / NCT00123942
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI-507 | Monoclonal antibody | — | — |